Key Takeaways HIMS surged 90.4% in three months, outpacing peers and driven by gains in online revenue and subscribers. Expansion into Canada and the ZAVA acquisition mark major international growth milestones for HIMS. HIMS projects up to 74% Q2 revenue growth and 63% full-year growth, fueled by demand for GLP-1 therapies.Hims & Hers Health, Inc.’s (HIMS) investors have been experiencing some short-term gains from the stock lately despite its bumpy ride over recent months. The San Francisco, CA-based hea ...